Meeting Banner
Abstract #0623

MRMI of Extradomain-B Fibronectin for Assessing Drug Resistance in Colon Cancer

Zheng-Rong Lu1, Amita Vaidya1, Nadia Ayat1, Helen Wang1, and Megan Buford1
1Biomedical Engineering, Case Western Reserve University, Cleveland, OH, United States

Non-invasive active surveillance and risk-stratification of drug-resistant colon cancer is imperative, in order to facilitate disease management and tailor therapeutic interventions. This research demonstrates that acquired drug resistance in colon cancer is associated with enhanced expression of extracellular matrix oncoprotein extradomain-B fibronectin (EDB-FN). MR molecular imaging of EDB-FN at a subclinical dose of macrocyclic ZD2-targeted contrast agent ZD2-N3-Gd(HP-DO3A) facilitates effective assessment of drug-resistant colon cancer in two independent models, highlighting the potential of EDB-FN as a diagnostic molecular marker for invasive colon cancer.

This abstract and the presentation materials are available to members only; a login is required.

Join Here